OVAC Sign-On Statement on Recent Executive Actions That Threaten Progress

As members of organizations unified in our support for the life-saving power of cancer research, we oppose recent executive actions that indisputably jeopardize progress in the fight against cancer today and for years to come.

Cuts to our nation's health and research infrastructure funding and widespread layoffs at the National Institutes of Health, including the National Cancer Institute, the Centers for Disease Control and Prevention, and the Food and Drug Administration will have a devastating impact on the more than 2 million people who will be diagnosed with cancer this year alone. The negative impact of cuts will be felt across the country where research generates significant economic activity and jobs in every state. The United States also risks losing its global competitive edge in biomedical research as these actions threaten to halt or end clinical trials, shutter sophisticated medical labs across the country, force young researchers to reconsider or abandon academic research and jeopardize Americans' access to the latest and best medical advancements, including new cancer treatments, for years to come.

We stand ready as a community to work with the administration and Congress to ensure we continue the progress that has driven a 34% reduction in cancer mortality over the past two decades. We call on the administration to stand with patients, researchers, caregivers, physicians, pharmacists, and nurses by reversing these harmful actions and continuing our nation's longstanding bipartisan support for cancer research and prevention.

Sincerely,

National Organizations (33)

  • American Association for Cancer Research
  • American Cancer Society Cancer Action Network
  • American Society for Radiation Oncology
  • Asbestos Disease Awareness Organization (ADAO)
  • Association of American Cancer Institutes
  • Children's Cancer Cause
  • Deadliest Cancers Coalition
  • Debbie's Dream Foundation: Curing Stomach Cancer
  • ECAN Esophageal Cancer Action Network
  • Fight Colorectal Cancer
  • Friends of Cancer Research
  • Global Liver Institute
  • GO2 for Lung Cancer
  • Head for the Cure Foundation
  • Hematology/Oncology Pharmacy Association
  • International Myeloma Foundation
  • LIVESTRONG
  • LUNGevity Foundation
  • Melanoma Research Foundation
  • METAvivor
  • National Brain Tumor Society
  • National Cancer Registrars Association
  • Oncology Nursing Society
  • Ovarian Cancer Research Alliance
  • Pancreatic Cancer Action Network (PanCAN)
  • Patient Empowerment Network
  • Pennsylvania Prostate Cancer Coalition
  • Society for Immunotherapy of Cancer
  • Society Gynecologic Oncology
  • The Leukemia & Lymphoma Society
  • The National Alliance of State Prostate Cancer Coalitions
  • The National Pancreas Foundation
U.S. Capitol Building
Advocacy

What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown

On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.

Map of the sub-Saharan African region
Advocacy

HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity

ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.

Images of DNA strands for DPYD genetic testing
Advocacy

HOPA Supports FDA Box Label Changes for DPYD Testing

We support the FDA's updated guidance concerning DPD deficiency and fluoropyrimidine drugs, and urge healthcare providers to integrate DPYD genetic testing into clinical practice.